CD95 _ FAS
- Known as:
- CD95 _ Fas Cell Surface Death Receptor
- Catalog number:
- AM08166RP-N
- Product Quantity:
- 100 Tests
- Category:
- -
- Supplier:
- ACR
- Gene target:
- CD95 _ FAS
Related genes to: CD95 _ FAS
- Gene:
- FAS NIH gene
- Name:
- Fas cell surface death receptor
- Previous symbol:
- FAS1, APT1, TNFRSF6
- Synonyms:
- CD95, APO-1
- Chromosome:
- 10q23.31
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-25
- Date modifiied:
- 2019-04-23
Related products to: CD95 _ FAS
Related articles to: CD95 _ FAS
- The diagnostic performance of CARTO FINDER system for repetitive focal activations (FAs) that may sustain atrial fibrillation (AF) remains under debate. - Source: PubMed
Publication date: 2026/06/20
Yokoyama HirotakeTakase SusumuMukai YasushiWatanabe TsukasaNagayama TomomiSakamoto KazuoTsutsui HiroyukiAbe Kohtaro - Food allergy (FA) significantly impairs health-related quality of life (HRQL), yet its key determinants remain unclear. This study aimed to identify factors associated with poor HRQL in FA using machine-learning analysis. - Source: PubMed
Publication date: 2026/06/19
Vera-Berrios Rosialzira NatashaGonzalo-Fernández AlejandroFreundt-Serpa NataliaMarco-Martín GuadalupeFernández-Parra BeatrizAlvarado-Izquierdo María IsabelCasas-Saucedo RocíoStein-Coronado CristinaIbáñez-Echevarría EthelRamos-García Taniade Durana María Dolores Alonso DíazLópez-Raigada AzaharaBlanco-Guerra Carlosde Calzada-Bustingorri María PíaCarrillo-Díaz TeresaSuárez Hilda Rianec HernándezDíaz-Palacios Miguel ÁngelInfante-Herrero SonsolesNieto-Nieto Ana MaríaCortés Sonia VázquezMancebo Eloína GonzálezEscribese María MNieto Pilar RicoBarber DomingoFernández-Rivas Montserrat - - Source: PubMed
Publication date: 2026/06/19
Tu YihuiXue HuamingFrancis WendyDavies Andrew PPallister IanKanamarlapudi VenkateswarluXia Zhidao - Previous research indicated that physicians possess limited knowledge of the diagnosis and treatment of invasive fungal disease (IFD). - Source: PubMed
Chen YijianHuang XiaojunQiu HaiboCheng LinlingYu YunsongMa XiaochunFeng SizhouLi QiWu DepeiHuang WenxiangChen DechangLv XiaojuHu JiandaWang JingboLi JiabinYang WenjieZhan QingyuanSun BingWang Minggui - Sulfated galactan (SG) isolated from has demonstrated promise for cancer therapy and prevention through inhibition of cancer cell proliferation and migration. However, its structure‑activity relationship remains to be elucidated. The present study evaluated the microstructural characteristics and anticancer activity, particularly immunogenic cell death (ICD)‑inducing potential, of SG and its degraded derivative (DSG) in triple‑negative breast cancer cells. SG and DSG were prepared and structurally characterized using gel permeation chromatography, nuclear magnetic resonance, Fourier‑transform infrared and scanning electron microscopy coupled with energy‑dispersive X‑ray spectroscopy. ICD induction was assessed in human MDA‑MB‑231 breast cancer cells using an MTT assay, phase‑contrast microscopy, Hoechst/propidium iodide dual staining, intracellular reactive oxygen species (ROS) generation assay, and transmission electron microscopy (TEM). In addition, western blot analysis, immunofluorescence staining, and reverse transcription‑quantitative PCR were performed. Structural analyses revealed that SG and DSG share similar backbone structures but differ markedly in sulfate content and molecular weight. Both compounds were non‑toxic to normal breast epithelial MCF‑10A cells and exhibited mild cytotoxicity toward MDA‑MB‑231 cells. DSG treatment induced notable morphological changes in cancer cells, with reduced cell numbers, increased membrane permeability and elevated intracellular ROS levels. TEM revealed DSG‑induced ultrastructural changes consistent with cellular stress and cytotoxicity. DSG also markedly upregulated ICD‑associated proteins [calreticulin (CRT) and Fas receptor (Fas‑R)] and endoplasmic reticulum stress‑related genes (protein kinase RNA‑like endoplasmic reticulum kinase, inositol‑requiring enzyme 1, activating transcription factor (ATF)6, ATF4, eukaryotic initiation factor 2 α subunit, CRT and Fas‑R), with effects similar to the positive control doxorubicin. Therefore, these findings indicated that DSG enhances ICD in triple‑negative breast cancer cells and may potentially serve as a promising ICD‑inducing adjuvant for cancer immunotherapy. - Source: PubMed
Publication date: 2026/06/19
Rudtanatip TawutPolsan YadaSakaew WarapornSomintara SomsudaPhanphak JenjiralaiEl-Abid JamalWongprasert KanokpanPariwatthanakun Choowadee